Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 12/20 | 0.72 |
| ▸ | RXRB | P28702 | 10/20 | 0.72 |
| ▸ | RARB | P10826 | 10/20 | 0.62 |
| ▸ | RARG | P13631 | 10/20 | 0.62 |
| ▸ | RXRG | P48443 | 6/20 | 0.62 |
| ▸ | RARA | P10276 | 8/20 | 0.62 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.62 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.62 |
| ▸ | CRABP2 | P29373 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5712092 | 0.89 | RARB (0.79) | RXRARXRBRARBRARGRXRG | |
| SCHEMBL8458824 | 0.84 | RXRA (1.00) | RXRARXRBRARBRARGRXRG | |
| SCHEMBL7422602 | 0.84 | RXRA (1.00) | RXRARXRBRARBRARGRXRG | |
| SCHEMBL8839089 | 0.83 | RXRA (0.69) | RXRARXRBRARBRARGRXRG | |
| SCHEMBL8557387 | 0.83 | RXRA (0.49) | RXRARXRBRARBRARGRXRG | |
| SCHEMBL8681591 | 0.82 | RXRA (0.71) | RXRARXRBRARBRARGRXRG | |
| SCHEMBL9519749 | 0.82 | RXRA (0.71) | RXRARXRBRARBRARGRXRG | |
| SCHEMBL21794444 | 0.81 | RXRA (0.70) | RXRARXRBRARBRARGRXRG | |
| SCHEMBL8093046 | 0.81 | RARB (0.64) | RXRARXRBRARBRARGRXRG | |
| SCHEMBL8100810 | 0.81 | RXRA (0.69) | RXRARXRBRARBRARGRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6992095-B2 | Stilbene compounds comprising an adamantyl group, compositions and methods thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2006-01-31 | — | — | US | disclosed |
| US-20040067971-A1 | Stilbene compounds comprising an adamantyl group, compositions and methods thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2004-04-08 | — | — | US | disclosed |
| US-20020010337-A1 | Stilbene compounds comprising an adamantyl group, compositions and methods thereof | BERNARDON JEAN-MICHEL (FR) | 2002-01-24 | — | — | US | disclosed |
| US-6214878-B1 | SKIN DISORDERS; RHEUMATIC DISEASES; RESPIRATORY SYSTEM DISORDERS; CARDIOVASCULAR DISORDERS; VISION DEFECTS | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2001-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067971-A1 | Stilbene compounds comprising an adamantyl group, compositions and methods thereof | SQLE, FDFT1, PIGS | RXRA 1230/4885RXRB 414/4885RARB 406/4885 |
| US-20020010337-A1 | Stilbene compounds comprising an adamantyl group, compositions and methods thereof | SQLE, FDFT1, PIGS | RXRA 1230/4885RXRB 414/4885RARB 406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.